David's coverage specializes in OTC medicines, dietary supplements and self-care medical devices. David is interested in regulatory gray areas such as the borderlines between medicines, supplements and medical devices, as well as botanical ingredients. David also regularly speaks to industry leaders and experts about the latest trends to deliver crucial market intelligence to HBW Insight readers, and co-hosts the Over the Counter podcast. In his spare time, David spends time in his allotment garden, reading/watching science fiction and worrying about climate change.
Latest from David Ridley
HBW Insight speaks to Kerry Group's RDA director for digestive health, Mathieu Millette, about the opportunity represented by the global trend for GLP-1 agonists for consumer health.
The Urban Wastewater Treatment Directive “in its current form, is at an end,” insists Pharma Deutschland CEO Jörg Wieczorek. To put the directive to bed once and for all, the association has applied for leave to intervene in the ongoing EU legal battle in its own right.
Haleon described the opening of a new oral care R&D facility in the UK as a “major investment reflecting our commitment to advancing science and innovation.”
Now available without a prescription, Dymista Control is the first OTC combination treatment for consumers who are struggling to control their seasonal allergic rhinitis with a corticosteroid or antihistamine nasal spray, according to the firm.
Gum health awareness among British consumers could be better, a recent Haleon survey finds.
Based on advice from its advisory committees, the UK's Food Standards Agency is encouraging businesses to meet an acceptable daily intake of 10mg CBD per day and a safe upper limit of 0.07mg THC per day.